Biotech announced that net profit attributable to owners of the parent company for the first half year of 2026 is expected to be -230 million yuan to -290 million yuan, and net profit for the same period last year is -125 million yuan. The increase in losses in the current period was mainly due to the year-on-year increase in R&D expenses of 28.67% to 40.14%, and the increase in expenses was greater than the increase in operating income.

Biotech announced that net profit attributable to owners of the parent company for the first half year of 2026 is expected to be -230 million yuan to -290 million yuan, and net profit for the same period last year is -125 million yuan. The increase in losses in the current period was mainly due to the year-on-year increase in R&D expenses of 28.67% to 40.14%, and the increase in expenses was greater than the increase in operating income.